About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Understanding Chronic Lymphocytic Leukemia | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT04028531

Understanding Chronic Lymphocytic Leukemia

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemi...

Lead sponsor: Dana-Farber Cancer Institute•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Jennifer Brown, MD, PhD

CONTACT

617-582-8437 [email protected]

Sponsors

Lead Sponsor

Dana-Farber Cancer Institute

Collaborators

National Cancer Institute (NCI)

The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia, for the potential development of more effective therapies for this disease.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•New and existing patients seen for treatment of monoclonal B-cell lymphocytosis
•Any low grade lymphoproliferative disorder
•Chronic Lymphocytic Leukemia in the Dana Farber Cancer Institute Hematologic Oncology Clinic or elsewhere

Exclusion Criteria

•\-

Related studies

RECRUITINGPhase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671 · CLL, Chronic Lymphocytic Leukemia

RECRUITINGPhase 4

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database

NCT06548152 · Chronic Lymphocytic Leukemia

Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma

NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)

RECRUITINGPhase 3

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231 · Chronic Lymphocytic Leukemia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 22, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment2,750

Start dateSep 1999

Last updatedJul 22, 2025

Condition

Chronic Lymphocytic Leukemia

Locations shown

Dana Farber Cancer Institute

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 22, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions